Rituximab reduces the incidence of acute graft-versus-host disease

To the editor: B lymphocytes are increasingly assigned a pivotal position in the pathogenesis of chronic auto- and alloimmune diseases. Clinical trials testing rituximab against multiple sclerosis,[1][1] rheumatoid arthritis,[2][2] systemic lupus erythematosus,[3][3] and steroid refractory chronic